Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 901–1,000 of 1,026
Wang, X., Wang, K., Yu, M., Velluto, D., Hong, X., Wang, B., Chiu, A., Melero-Martin, J. M., Tomei, A. A., & Ma, M. (2022) · Science Advances · doi:10.1126/sciadv.abn0071 · Cited by 62
“PD-1 (CD279) and CTLA-4 (CD152) are two critical and potent regulators of peripheral T cell tolerance and T cell function (42, 43); these two signaling pathways have been used in modulating alloreactive responses in multiple transplantation models.”
BackgroundRuiz-Martínez, Á., Gong, C., Wang, H., Sové, R. J., Mi, H., Kimko, H. H. C., & Popel, A. S. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010254 · Cited by 70
“Over the last decade, immunotherapies with ICBs have demonstrated promising clinical outcomes and increase in survival rates in different types of advanced cancer [11,12,13].”
BackgroundColorectal cancer vaccines: The current scenario and future prospects
Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62
“Also, CD4+ T-helper cells (Th1) in different compartments activate DCs through CD40/CD40L interaction and equip tumor cells with more MHC I on the surface by releasing IFNg, orchestrating various cell types and contributing to an inflammatory environment (10, 11).”
BackgroundSahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 73
Lordick, F., Mauer, M., Stocker, G., Cella, C. A., Ben‐Aharon, I., Piessen, G., Wyrwicz, L., Al-Haidari, G., Fleitas, T., Boige, V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.829 · Cited by 64
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
“When patients do not respond to ICBs immediately following start of ially but relapse over time, secondary resistance to ICB-treatment has developed. in metastatic melanoma: Robert et al. NEJM 2011, Schachter et al. ASCO #9504 2016. time of checkpoint engagement in the T-cell response.”
BackgroundInfluentialEmerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
“Malignant cells from different origin (and associated stromal cells) express indeed high levels of PD-L1, which turns off effector T cells and NK cells in a PD-1-dependent manner [95].”
BackgroundRecent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
Sadozai, H., Gruber, T., Hunger, R. E., & Schenk, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01617 · Cited by 67
Liu, Y., Dong, Z., Jiang, T., Hou, L., Wu, F., Gao, G., He, Y., Zhao, J., Li, X., Zhao, C., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.008 · Cited by 64
Linette, G. P., Becker-Hapak, M., Skidmore, Z. L., Baroja, M. L., Xu, C., Hundal, J., Spencer, D. H., Fu, W., Cummins, C., Robnett, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906026116 · Cited by 62
“Therapeutic vaccination and related interventions that facilitate antigen cross-presentation in secondary lymphoid organs will likely be required to increase the breadth, diversity, and frequency of neoantigen-specific CD8+ T cells as an adjunct to checkpoint inhibitor treatment for cancer (32).”
BackgroundTerzuoli, E., Bellan, C., Aversa, S., Ciccone, V., Morbidelli, L., Giachetti, A., Donnini, S., & Ziche, M. (2019) · Cancers · doi:10.3390/cancers11121963 · Cited by 65
“In all profiles, the intrinsic tumorigenicity of tumor cells and the state of activated T cell immunity or tolerance play a pivotal role [31].”
BackgroundInfluentialSantos, J. M., Heiniö, C., Cervera-Carrascón, V., Quixabeira, D. C. A., Siurala, M., Havunen, R., Bützow, R. C., Zafar, S., de Gruijl, T. D., Lassus, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000188 · Cited by 64
“53 This is not surprising since PD-L1 expression in tumors also defines a previously immunologically active tumor, 54 which has developed the ability to silence adaptive immunity.”
Zhang, J., Wu, Z., Zhang, X., Liu, S., Zhao, J., Yuan, F., Shi, Y., & Song, B. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000910 · Cited by 66
Höppener, D. J., Galjart, B., Nierop, P. M. H., Buisman, F. E., van der Stok, E. P., van den Braak, R. R. J. C., van Amerongen, M. J., Balachandran, V. P., Jarnagin, W. R., Kingham, T. P., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab026 · Cited by 59
“Because of their genetic hypermutability, MSI tumors express more mutational neoantigens, which can become targets for T cells (18,19).”
Roles of Notch Signaling in the Tumor Microenvironment
D’Assoro, A. B., Leon-Ferre, R. A., Braune, E.-B., & Lendahl, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116241 · Cited by 65
Enhanced development of functional human NK cells in NOD‐ scid‐IL2rg null mice expressing human IL15
Aryee, K., Burzenski, L. M., Yao, L., Keck, J., Greiner, D. L., Shultz, L. D., & Brehm, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202200045r · Cited by 63
Rational design of ICD-inducing nanoparticles for cancer immunotherapy
Zhang, Z., Pan, Z., Li, Q., Huang, Q., Shi, L., & Liu, Y. (2024) · Science Advances · doi:10.1126/sciadv.adk0716 · Cited by 72
Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application
Pan, Y., Zhou, H., Sun, Z., Zhu, Y., Zhang, Z., Han, J., Liu, Y., & Wang, Q. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07544-w · Cited by 75
“Tregs in fl uence the ef fi cacy of solid tumor immunotherapies by reshaping the TME The immunosuppressive TME is an important marker of tumor emergence and the basis of resistance and immune escape after immunotherapy [64].”
Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy
van Dam, P., Daelemans, S., Ross, E. L., Waumans, Y., Laere, S. V., Latacz, E., Steen, R. V., Pooter, C. D., Kockx, M. M., Dirix, L. Y., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.009 · Cited by 66
Heeren, A. M., Rotman, J., Stam, A. G. M., Pocorni, N., Gassama, A. A., Samuels, S., Bleeker, M. C. G., Mom, C. H., Zijlmans, H. J. M. A. A., Kenter, G. G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0526-z · Cited by 68
Czystowska, M., & Whiteside, T. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1813276 · Cited by 61
“Over the last decade, an increasing number of studies has provided evidence that tumors develop diverse and powerful defensive strategies to protect themselves from the host responses [1].”
BackgroundGroeneveldt, C., Kinderman, P., van den Wollenberg, D. J. M., van den Oever, R. L., Middelburg, J., Mustafa, D. A. M., Hoeben, R. C., van der Burg, S. H., van Hall, T., & van Montfoort, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001191 · Cited by 59
Franchini, D.-M., Lanvin, O., Tosolini, M., Patras de Campaigno, E., Cammas, A., Péricart, S., Scarlata, C.-M., Lebras, M., Rossi, C., Ligat, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.014 · Cited by 61
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival
Kellish, P. C., Shabashvili, D. E., Rahman, M. M., Nawab, A., Guijarro, M. V., Zhang, M., Cao, C., Moussatché, N., Boyle, T. A., Antonia, S. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121323 · Cited by 64
Herrera, A. F., Goy, A. H., Mehta, A., Ramchandren, R., Pagel, J. M., Svoboda, J., Guan, S., Hill, J. S., Kwei, K. A., Liu, E. A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25659 · Cited by 64
Lin, Y., Pan, X., Zhao, L., Yang, C., Zhang, Z., Wang, B., Gao, Z., Jiang, K., Ye, Y., Wang, S., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00249-x · Cited by 68
TSH-TSHR axis promotes tumor immune evasion
Wu, Z., Xi, Z., Xiao, Y., Zhao, X., Li, J., Feng, N., Hu, L., Zheng, R., Zhang, N., Wang, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004049 · Cited by 72
Melanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 77
Castellanos-Rueda, R., Roberto, R. B. D., Bieberich, F., Schlatter, F. S., Palianina, D., Nguyen, O. T. P., Kapetanovic, E., Laubli, H. P., Hierlemann, A. R., Khanna, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34141-8 · Cited by 71
Shen, J., Choi, Y., Lee, T., Kim, H., Chae, Y. K., Dulken, B. W., Bogdan, S., Huang, M., Fisher, G. A., Park, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008339 · Cited by 69
“The final optimized Lunit SCOPE IO model was applied to an independent real-world data set (N=1,806 patients) of H&E-stained WSIs scanned at 40× magnification (0.25 µm per pixel), derived from pre-ICI treatment formalin-fixed, paraffin-embedded (FFPE) surgical resection and biopsy specimens with…”
MethodInfluentialJanikovits, J., Müller, M., Krzykalla, J., Körner, S., Echterdiek, F., Lahrmann, B., Grabe, N., Schneider, M. A., Benner, A., Doeberitz, M. V. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1390640 · Cited by 65
Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
Kim, S.-S., Harford, J. B., Moghe, M., Rait, A., & Chang, E. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484982 · Cited by 60
Gonçalves, P. B., & Romeiro, N. C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.020 · Cited by 63
Roles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 65
Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Mohammad, G. R. K. S., Ghahremanloo, A., Soltani, A., Fathi, E., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29491 · Cited by 66
“Some of the detailed information about the immune checkpoints have been reviewed comprehensively by Chen and Mellman (2017); Ribas and Wolchok (2018); Sanmamed and Chen (2018); Sun, Mezzadra, and Schumacher, (2018).”
BackgroundProgress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Filipović, A., Miller, G., & Bolen, J. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00155 · Cited by 64
“…of both response and resistance to CPIs, ideally at an individual patient level, would be of significance for further tailoring the use of approved immunotherapies and for more rapid and successful development of novel immunotherapeutic approaches (Blank et al., 2016; Chen and Mellman, 2017).”
BackgroundDecoding Cancer Biology One Cell at a Time
Castro, L. N. G., Tirosh, I., & Suvà, M. L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1376 · Cited by 59
“Not surprisingly, T cells have attracted the most attention due to their critical role in the efficacy of immunotherapies (72).”
BackgroundRecent advances of nanotechnology-based tumor vessel-targeting strategies
Zhu, D., Li, Y., Zhang, Z., Xue, Z., Hua, Z., Luo, X., Zhao, T., Lu, C. C., & Liu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01190-y · Cited by 62
“However, there is still a significant proportion of patients who do not respond to ICB and benefit from it [80].”
BackgroundNKG7 Is Required for Optimal Antitumor T-cell Immunity
Li, X.-Y., Corvino, D., Nowlan, B., Aguilera, A. R., Ng, S. S., Braun, M., Cillo, A. R., Bald, T., Smyth, M. J., & Engwerda, C. R. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0649 · Cited by 63
“C and D, Some groups of C57BL/6J WT or Nkg7 / (n 1⁄4 4–6) mice were additionally treated with 100 mg control Ig (1-1), or 100 mg antiCD4 (GK1.”
MethodVISTA expression and patient selection for immune-based anticancer therapy
Martin, A. S., Molloy, M., Ugolkov, A. V., Roemeling, R. W. V., Noelle, R. J., Lewis, L. D., Johnson, M. L., Radvanyi, L. G., & Martell, R. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086102 · Cited by 64
“This pattern demonstrated the best response to anti-PD-1/PD-L1 therapy (82, 83).”
Zhou, Z., Wang, J., Wang, J., Yang, S., Wang, R., Zhang, G., Li, Z., Shi, R., Wang, Z., & Lu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02047-2 · Cited by 72
“3 ) [45, 46].”
Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 77
“Both CTLA4 and PD-1 act as “brakes” of the immune system and their inhibition restores antitumoral immunity against different types of cancer [3].”
Bolen, C. R., McCord, R., Huet, S., Frampton, G. M., Bourgon, R., Jardin, F., Dartigues, P., Punnoose, E. A., Szafer‐Glusman, E., Xerri, L., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000786 · Cited by 67
“However, ultimately, the most useful biomarker of response in FLwill be one that defines a general immune set point relevant for therapies like rituximab and anti–PD-1/PD-L1.(36) The pronounced PFS benefit of rituximab maintenance among FL patients with low mutation loads treated with R-chemotherapy is novel, and the…”
BackgroundShen, P., Jing, Y., Zhang, R., Cai, M., Ma, P., Chen, H., & Zhuang, G. (2018) · Oncogene · doi:10.1038/s41388-018-0192-5 · Cited by 60
“[10] might have promising efficacy against NEBC.”
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Xie, G., Tan, C., Lin, J., Zhang, L., Zheng, J., Liu, Y., Xie, G., Wang, B., & Yuan, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0401-3 · Cited by 65
“Nevertheless, only a subset of patients exhibit durable responses and nearly 70% of patients cannot generate any response to a single-agent strategies for most kinds of tumors [2].”
BackgroundMicrobiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer
Bellone, M., Brevi, A., & Huber, S. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00064-19 · Cited by 65
Immunotherapy for pancreatic cancer
Yoon, J. H., Jung, Y.-J., & Moon, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2969 · Cited by 69
Jiménez‐Cortegana, C., Carrión, N. P., Martín, A., Nogales‐Fernández, E., Carnicero-González, F., Ríos, E., de la Cruz‐Vicente, F., Rodríguez‐García, G., Fernández-Álvarez, R., Rueda‐Domínguez, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002323 · Cited by 60
The Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 66
“org 2 cells in the tumor bed, with immune cells only at the invasive margin (immune excluded tumors) (12).”
BackgroundNowak-Sliwinska, P. M., van Beijnum, J. R., Griffioen, C. J., Huinen, Z. R., Sopesens, N. G., Schulz, R., Jenkins, S. V., Dings, R. P. M., Groenendijk, F. H., Huijbers, E. J. M., et al. (2022) · Angiogenesis · doi:10.1007/s10456-022-09863-4 · Cited by 66
The roles and mechanisms of SREBP1 in cancer development and drug response
He, Y., Qi, S., Chen, L., Zhu, J., Liang, L., Chen, X., Zhang, H., Zhuo, L., Zhao, S., Liu, S., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.022 · Cited by 73
“44 Immunity response and TME play a crucial role in cancer immunotherapy.”
BackgroundLin, Y., Jing, X., Chen, Z., Pan, X., Xu, D., Yu, X., Zhong, F., Zhao, L., Yang, C., Wang, B., et al. (2023) · Theranostics · doi:10.7150/thno.86928 · Cited by 68
“Researchers have reported that solid tumors can be divided into immunoinflammatory types (“hot” tumors) and immune exclusion types (“cold” tumors) based on TME characteristics [47-49].”
Xu, F., Wang, X., Huang, Y., Zhang, X., Sun, W., Du, Y., Xu, Z., Kou, H., Zhu, S., Liu, C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113424 · Cited by 67
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 80
Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics
Qiao, L., Niu, L., Wang, Z., Deng, Z., Di, D., Ma, X., Zhou, Y., Kong, D., Wang, Q., Yin, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00932-3 · Cited by 80
“Strong immune activation is expected to produce an immune memory effect that can protect against tumor metastasis 36 .”
Gullo, I., Oliveira, P., Athelogou, M., Gonçalves, G., Pinto, M. L., Carvalho, J., Valente, A., Pinheiro, H. C., Andrade, S., Almeida, G. M., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0836-8 · Cited by 65
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann, S., Peters, S., Owinokoko, T., & Gadgeel, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201319 · Cited by 62
Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma
Blasi, D. D., Boldanova, T., Mori, L., Terracciano, L., Heim, M. H., & Libero, G. D. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.08.004 · Cited by 65
“Comparison of TIL Phenotype Correlates With Tumor Immunohistologic Profile An important classification of tumors relies on the presence of mononuclear cell infiltrate (immune-inflamed, immune-excluded, and immune-desert) within tumor tissue.(6) To investigate potential correlations between the presence of immune infil…”
BackgroundMethodInfluentialThe role of exosomal PD-L1 in tumor immunotherapy
Wang, J., Zeng, H., Zhang, H., & Han, Y. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101047 · Cited by 58
The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy
Zhao, J., Zhong, S., Niu, X., Jiang, J., Zhang, R., & Li, Q. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12804 · Cited by 61
Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors
Shi, S., Gu, S. S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0778 · Cited by 60
“However, most patients develop primary or acquired resistance to immunotherapy (3, 4), highlighting the importance of identifying biomarkers and regulators of tumor immune response (5).”
BackgroundSu, Z., Xiao, Z., Huang, J., Wang, Y., An, Y., Xiao, H. P., Peng, Y., Pang, P., Han, S., Zhu, K., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c20422 · Cited by 57
Zhan, L., Feng, H.-F., Liu, H., Guo, L., Chen, C., Yao, X.-L., & Sun, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649863 · Cited by 65
Yin, Y., Lin, Y., Yang, M., Lv, J., Liu, J., Wu, K., Liu, K., Li, A., Shuai, X., Cai, K., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.959295 · Cited by 62
“PDL1 binding with PD-1, an immunoinhibitory receptor expressed on T cells, thus suppresses T-cell-mediated immune responses (4).”
BackgroundAutophagy in Cancer Immunotherapy
Lei, Y., Zhang, E., Bai, L., & Li, Y. (2022) · Cells · doi:10.3390/cells11192996 · Cited by 65
“Immune checkpoint blockade (ICB) therapy, with PD-1/PD-L1 blockade therapy as the most typical representative, has become one of the most popular immunotherapies today, and has significantly changed the current cancer treatment landscape [1].”
BackgroundVornholz, L., Isay, S. E., Kurgyis, Z., Strobl, D. C., Loll, P., Mosa, M. H., Luecken, M. D., Sterr, M., Lickert, H., Winter, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.add8564 · Cited by 62
“ICIs relieve inhibitory signals (check-points) from receptors such as PD1 or CTLA4 on tumor-infiltrating lymphocytes (TILs), which are frequently usurped by cancer cells, and thereby restore antitumor immunity via CD8 + cytotoxic T lymphocytes (CTLs) ( 2 ).”
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
Tojjari, A., Saeed, A. M., Singh, M., Cavalcante, L. L., Şahin, İ. H., & Saeed, A. (2023) · Vaccines · doi:10.3390/vaccines11081357 · Cited by 69
“Researchers suggest combining peptide-based vaccines with other immune-based treatments, like immune checkpoint inhibitors, to enhance the overall antitumor effect [37].”
BackgroundImmuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses
Cubas, R. A., Москаленко, М., Cheung, J., Yang, M. X., McNamara, E., Xiong, H., Hoves, S., Ries, C. H., Kim, J. G., & Gould, S. E. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800275 · Cited by 60
Zhu, Y., Wang, X., Zhang, Y., Xu, D., Dong, J., Zhang, Z., Yi, C., Jia, H., & Yang, X. L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s172719 · Cited by 59
Rod-Scale Design Strategies for Immune-Targeted Delivery System toward Cancer Immunotherapy
Wang, X., Ihara, S., Li, X., Ito, A., Sogo, Y., Watanabe, Y., Yamazaki, A., Tsuji, N. M., & Ohno, T. (2019) · ACS Nano · doi:10.1021/acsnano.9b01271 · Cited by 57
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
Lupi, I., Brancatella, A., Cosottini, M., Viola, N., Lanzolla, G., Sgrò, D., Dalmazi, G. D., Latrofa, F., Caturegli, P., & Marcocci, C. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0102 · Cited by 69
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 62
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Adoptive T-cell therapy for HBV-associated HCC and HBV infection
Tan, A. T., & Schreiber, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104748 · Cited by 71
Li, S., Bennett, Z. T., Sumer, B. D., & Gao, J. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00475 · Cited by 60
Pose, E., Coll, M., Martínez‐Sánchez, C., Zeng, Z., Surewaard, B. G. J., Català, C., Velasco‐de Andrés, M., Lozano, J. J., Ariño, S., Fuster, D., et al. (2021) · Hepatology · doi:10.1002/hep.31644 · Cited by 54
“(17) Importantly, blocking of the PD- 1/PDL1 pathway has been shown to induce immunological response to cancer cells and has carried a change of paradigm for the treatment of different cancers.(16,17)”
Immune Privilege of Heart Valves
Hill, M. A., Kwon, J. H., Gerry, B., Hardy, W. A., Walkowiak, O. A., Kavarana, M. N., Nadig, S. N., & Rajab, T. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731361 · Cited by 64
“There are a very large number of possible cancer mutations, and each type of cancer may possess unique mechanisms of immune privilege depending on the mutations it has accrued (21).”
BackgroundInfluentialLong, J., Wang, D., Wang, A., Chen, P., Lin, Y. S., Bian, J., Yang, X., Zheng, M., Zhang, H., Zheng, Y., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01024-y · Cited by 63
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Duvall, J. R., Thomas, J. D., Bukhalid, R. A., Catcott, K. C., Bentley, K. W., Collins, S. D., Eitas, T. K., Jones, B. D., Kelleher, E. W., Lancaster, K. L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00907 · Cited by 58
Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy
Nguyen, D. C., Song, K., Jokonya, S., Yazdani, O., Sellers, D. L., Wang, Y., Zakaria, A., Pun, S. H., & Stayton, P. S. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01310 · Cited by 57
Zhang, Y., Yan, Y., Liu, J., Xia, H., Zhou, J., Cui, Y., Huang, X., Chang, J., Zhang, W., Chen, W., et al. (2025) · Advanced Materials · doi:10.1002/adma.202501953 · Cited by 75
Dai, S., Chen, Y., Cai, W., Dong, S., Zhao, J., Chen, L., & Cheng, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01739-6 · Cited by 74
“Immune-desert tumors, by comparison, are devoid of significant lymphocytic infiltration, reflecting more profound deficits in immune priming [128, 130, 131].”
Pan-urologic cancer genomic subtypes that transcend tissue of origin
Chen, F., Zhang, Y., Bossé, D., Lalani, A. A., Hakimi, A. A., Hsieh, J. J.-D., Choueiri, T. K., Gibbons, D. L., Ittmann, M., & Creighton, C. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00289-x · Cited by 63
“c2 (333) BLCA (28), PRAD (59), KIRP (6), KIRC (5) PRAD:ERG fusion, PRAD:iCluster2, PRAD:meth.”
Ji, X., Wang, E., & Tian, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.120 · Cited by 57
“Blocking the PD-L1/PD-1 signaling can reverse immune suppression and enhance anti-tumor response [26].”
BackgroundExtracellular vesicles: important collaborators in cancer progression
Sato, S., & Weaver, A. M. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170080 · Cited by 60
Huang, Z., Xie, N., Liu, H., Wan, Y., Zhu, Y., Zhang, M., Tao, Y., Zhou, H., Liu, X., Hou, J., et al. (2019) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12927 · Cited by 64
Xie, X., Ma, L., Zhou, Y., Shen, W., Xu, D., Dou, J., Shen, B., & Zhou, C. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115223 · Cited by 61
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 57
Ling, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., Tan, F., Tao, X., Wang, S., Wang, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00135-2 · Cited by 62
Gu, X., Guan, J., Xu, J. X., Zheng, Q., Chen, C., Yang, Q., Huang, C., Wang, G., Zhou, H., Chen, Z., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02691-4 · Cited by 61
“Currently, ICIs are the most successful class of immune therapeutics, both as monotherapy and combination therapy [6].”
BackgroundBagherifar, R., Kiaie, S. H., Hatami, Z., Ahmadi, A., Sadeghnejad, A., Baradaran, B., Jafari, R., & Javadzadeh, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00861-0 · Cited by 58
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 64
Methods for monitoring cancer cell pyroptosis
Wang, S., Liu, Y., Zhang, L., & Sun, Z. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0504 · Cited by 60
“Consistent with the requirements of investigators, the related markers can be used to monitor pyroptosis by: (1) monitoring the cleavage of GSDMB/C/D/E, (2) monitoring the activation of caspases-1/3/4/5/8/11 and GzmA/ GzmB to determine the signal transduction pathway, and (3) monitoring the release of pyroptosis subst…”
BackgroundGastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches
Choi, S., Park, S., Kim, H., Kang, S. Y., Ahn, S., & Kim, K. (2022) · Biomedicines · doi:10.3390/biomedicines10030543 · Cited by 61
“Each phenotype displayed distinct biological characteristics, and tumors with an inflamed phenotype showed increased PDL1 expression by tumor and immune cells as well as a better response to ICI treatment compared to other phenotypes [68,69].”
BackgroundAdvanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 56
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 62
“PD-L1 expressed on tumor stroma interacts with PD-1 of T cells and generates an intracellular inhibitory signal [105].”
BackgroundBiomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
Gyurdieva, A. V., Zajic, S. C., Chang, Y.-F., Houseman, E. A., Zhong, S., Kim, J., Nathenson, M. J., Faitg, T. H., Woessner, M. A., Turner, D. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32491-x · Cited by 58
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Huang, S., Pan, C., Lin, Y., Chen, M., Chen, Y., Jan, C., Wu, C., Lin, F., Wang, S. Y., Lin, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202206856 · Cited by 74
Schmid, P., Turner, N. C., Barrios, C. H., Isakoff, S. J., Kim, S., Sablin, M., Saji, S., Savas, P. S., Vidal, G. A., Oliveira, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2084 · Cited by 59
“It was previously reported that treatment bene fi t from immunotherapy is reduced in tumors with low immune in fi ltration compared with immune-in fi ltrated tumors (26).”
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.